American Indians/Alaska Natives Have Elevated COVID-19 Mortality
American Indians/Alaska Natives (AI/ANs) have disproportionate COVID-19 mortality rates.
Emerging Treatments
Considerations for Hydroxychloroquine Use in Patients With Diabetes
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
Merck Collaborating on Novel COVID-19 Vaccine, Oral Antiviral
The vaccine candidate is currently in preclinical development with clinical studies expected to begin later this year.
High Dose IVIG to Be Investigated for Severe COVID-19 in Phase 3 Trial
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Hydroxychloroquine With or Without Azythromycin for COVID-19 Treatment Associated With Increased Risk for QTc Prolongation
Patients treated with hydroxychloroquine alone or in combination with azithromycin for pneumonia associated with COVID-19 were found to be at increased risk for corrected QT interval prolongation.
Generic Version of Antifungal Drug Mycamine Now Available
Fresenius Kabi announced the launch of Micafungin for Injection, a generic version of Mycamine (micafungin for injection; Astellas Pharma).
Microbiome-Based Therapy Looks Promising for Recurrent C Difficile Infection
“These positive preliminary findings represent a major step forward towards bringing an innovative, non-antibiotic option to patients that may help restore their gut microbiome,” said Per Falk, Ferring’s President and Chief Science Officer.
Pipeline: Immunotherapies and Other Investigational Therapies for COVID-19
While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.
COVID-19 mRNA Vaccine Candidates Advancing Through the Pipeline
A phase 2 study of Moderna’s vaccine candidate for COVID-19, mRNA-1273, is expected to start shortly following the Food and Drug Administration’s review of the Company’s Investigational New Drug (IND) application.
Recarbrio Noninferior to Pip/Tazo for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
-
Loading...
-
Loading...
Next post in Respiratory
